Labcorp launches FDA-approved PTEN test for prostate cancer
Labcorp (NYSE:LH) said the FDA-approved Roche VENTANA PTEN (SP218) RxDx Assay is now available nationwide. The test detects PTEN protein loss in prostate adenocarcinoma tissue to identify patients who may qualify for AstraZeneca’s TRUQAP (capivasertib) with abiraterone and prednisone, according to Labcorp. The assay is offered via Labcorp’s lab network.
How this was made
The 30-second read
Why it matters
By enabling biomarker-based treatment eligibility for AstraZeneca’s TRUQAP regimen, the assay can drive additional testing orders through Labcorp’s national lab network.
Market read
This is a concrete, regulatory-linked product availability update for LH’s oncology testing services, potentially supporting incremental demand tied to TRUQAP eligibility.
What to watch
Adoption depends on clinician uptake, payer coverage, and how frequently TRUQAP is prescribed with abiraterone and prednisone for PTEN-loss patients.
Background
The VENTANA PTEN (SP218) RxDx Assay is an FDA-approved immunohistochemistry companion diagnostic used to detect PTEN protein loss in prostate adenocarcinoma tissue.
Ticker impact
Labcorp (LH) announced nationwide availability of Roche’s FDA-approved VENTANA PTEN (SP218) companion diagnostic for prostate cancer treatment selection.
Near-term sentiment positive for LH on incremental test volume expectations; magnitude likely limited without quantified revenue impact.
The article is a fresh product availability/regulatory-linked rollout for LH’s lab network, but it provides no financial guidance, adoption metrics, or timeline beyond “nationwide availability.”
Market effects
Strengthens the precision-oncology companion diagnostic testing value chain for lab services and biomarker-driven oncology.
Primarily US-focused rollout via Labcorp’s national network.
Moderate, as it is tied to Roche’s assay and AstraZeneca’s TRUQAP eligibility framework.
Counterpoint
Without disclosed expected volumes or reimbursement details, the market may treat this as incremental rather than material to LH earnings.
Key entities
- companyLabcorp
Announced nationwide availability of the FDA-approved VENTANA PTEN (SP218) companion diagnostic through its lab network.
- companyRoche
Assay developer whose VENTANA PTEN (SP218) RxDx Assay received FDA approval and is now available via Labcorp.
- companyAstraZeneca
TRUQAP (capivasertib) is the associated therapy for patients identified as PTEN protein loss by the assay.
